Flucytosine: Updated recommendations for the use in patients with dihydropyrimidine dehydrogenase (DPD) deficiency
About
This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.
Documents
Key facts
| Active substance |
Flucytosine
|
| Procedure number |
EMEA/H/A-31/1481
|
| Regulatory outcome |
Variation
|
| DHPC type |
Referral - Article 31
|
| Referral name |
Fluorouracil and fluorouracil related substances (capecitabine, tegafur and flucytosine) containing medicinal products
|
| Human ATC code |
J02AX01
|
| Dissemination date |
04/06/2020
|